Higher Trough Concentrations of Infliximab are Associated with Clinical Remission and Mucosal Healing in Patients with Inflammatory Bowel Disease

There is increasing evidence that clinical remission (CR) and mucosal healing (MH) are associated with better response to treatment, less hospitalization, lower surgery rates, and improved quality of life in patients with inflammatory boweldisease (IBD). 

Infliximab (IFX), an anti-tumor necrosis factor alpha (TNF-α) antibody, has promoted MH and improved long-term outcomes in patients with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC). Despite its effectiveness in both induction and maintenance of remission, a substantial number of patients will eventually loose response. Sustained response, long-term CR and complete MH have become major goals in IBD therapy. Read more>>>>>>>>>>>>>>>